Abstract
Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR <2. Among younger patients (age
| Original language | English |
|---|---|
| Pages (from-to) | 1875-1883 |
| Number of pages | 9 |
| Journal | Annals of Hematology |
| Volume | 94 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 22 2015 |
Fingerprint
Keywords
- Granulocyte
- ISS
- Lymphocyte
- Multiple myeloma
ASJC Scopus subject areas
- Hematology
- Medicine(all)
Cite this
Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. / Romano, A.; Parrinello, N. L.; Consoli, M. L.; Marchionni, L.; Forte, S.; Conticello, C.; Pompa, A.; Corso, A.; Milone, G.; Di Raimondo, F.; Borrello, I.
In: Annals of Hematology, Vol. 94, No. 11, 22.11.2015, p. 1875-1883.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents
AU - Romano, A.
AU - Parrinello, N. L.
AU - Consoli, M. L.
AU - Marchionni, L.
AU - Forte, S.
AU - Conticello, C.
AU - Pompa, A.
AU - Corso, A.
AU - Milone, G.
AU - Di Raimondo, F.
AU - Borrello, I.
PY - 2015/11/22
Y1 - 2015/11/22
N2 - Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR <2. Among younger patients (age
AB - Recent reports identify the ratio between absolute neutrophil count (ANC) and absolute lymphocyte count (ALC), called neutrophil to lymphocyte ratio (NLR), as a predictor of progression-free survival (PFS) and overall survival (OS) in various malignancies. We retrospectively examined the NLR in a cohort of 309 newly diagnosed multiple myeloma (MM) patients treated upfront with novel agents. NLR was calculated using data obtained from the complete blood count (CBC) at diagnosis and subsequently correlated with PFS and OS. The median NLR was 1.9 (range 0.4–15.9). Higher NLR was independent of international staging system (ISS) stage, plasma cell infiltration or cytogenetics. The 5-year PFS and OS estimates were, respectively, 18.2 and 36.4 % for patients with NLR ≥ 2 versus 25.5 and 66.6 % in patients with NLR <2. Among younger patients (age
KW - Granulocyte
KW - ISS
KW - Lymphocyte
KW - Multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=84941993505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941993505&partnerID=8YFLogxK
U2 - 10.1007/s00277-015-2462-4
DO - 10.1007/s00277-015-2462-4
M3 - Article
C2 - 26223359
AN - SCOPUS:84941993505
VL - 94
SP - 1875
EP - 1883
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 11
ER -